BindingDB Data by Journal
PMID
Data
Article Title
Citation
Organization
Download Data
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design.
J Med Chem 68: 18-48 (0)
Qingdao University of Science and Technology
A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment.
J Med Chem 68: 49-80 (0)
Shenyang Pharmaceutical University
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein.
J Med Chem 68: 81-94 (0)
University of South Florida
Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.
J Med Chem 68: 108-134 (0)
Nanjing University of Chinese Medicine
Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents.
J Med Chem 68: 156-173 (0)
China Pharmaceutical University
Structure-Based Development of Novel Spiro-Piperidine ASH1L Inhibitors.
J Med Chem 68: 174-195 (0)
University of Michigan
Minimalist Natural ORPphilin Macarangin B Delineates OSBP Biological Function.
J Med Chem 68: 196-211 (0)
Universite Paris-Saclay
Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease.
J Med Chem 68: 212-235 (0)
China Pharmaceutical University
Identification of an Isoxazole Derivative as an Antitubercular Compound for Targeting the FadD Enzymes of Mycobacterium tuberculosis.
J Med Chem 68: 270-286 (0)
India Institute of Science
Identification of Novel Human 15-Lipoxygenase-2 (h15-LOX-2) Inhibitors Using a Virtual Screening Approach.
J Med Chem 68: 307-323 (0)
University of Sao Paulo
Fluorinated Coumarin Derivatives as Selective PET Tracer for MAO-B Imaging.
J Med Chem 68: 324-337 (0)
Beijing Normal University
Design, Synthesis, and Biological Evaluation of 2-Arylaminopyrimidine Derivatives as Dual Cathepsin L and JAK Inhibitors for the Treatment of Acute Lung Injury.
J Med Chem 68: 361-386 (0)
Zhejiang University
Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions.
J Med Chem 68: 405-420 (0)
University of Michigan
Design, Synthesis, and Antitumor Activity Evaluation of 2-Phenylthiazole-5-Carboxylic Acid Derivatives Targeting Transactivation Response RNA-Binding Protein 2.
J Med Chem 68: 421-447 (0)
Chengdu Institute of Biology
Probing the Histamine H1 Receptor Binding Site to Explore Ligand Binding Kinetics.
J Med Chem 68: 448-464 (0)
Vrije Universiteit Amsterdam
The Discovery of a Novel AXL/Triple Angiokinase Inhibitor Based on 6-Chloro-Substituted Indolinone and Side Chain Methyl Substitution Inhibiting Pancreatic Cancer Growth and Metastasis.
J Med Chem 68: 465-490 (0)
Sun Yat-sen University
Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε.
J Med Chem 68: 506-530 (0)
Goethe University
Discovery of N-Phenyl-5-propyl-1H-pyrazole-3-carboxamide, with Selective Inhibition and Degradation of HDAC6 for the Treatment of Acute Liver Injury.
J Med Chem 68: 531-554 (0)
Anhui Medical University
Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention.
J Med Chem 68: 590-637 (0)
Schrodinger Inc.
Impact of Linker Composition on VHL PROTAC Cell Permeability.
J Med Chem 68: 638-657 (0)
Uppsala University
Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example.
J Med Chem 68: 674-694 (0)
Eberhard Karls University Tuebingen
F-CPI: A Multimodal Deep Learning Approach for Predicting Compound Bioactivity Changes Induced by Fluorine Substitution.
J Med Chem 68: 706-718 (0)
East China Normal University
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.
J Med Chem 68: 719-752 (0)
Cardiff University
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
J Med Chem 68: 753-775 (0)
Nanjing University of Chinese Medicine
Discovery of Novel 4,5,6,7-Tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one Derivatives as Orally Efficacious ATX Allosteric Inhibitors for the Treatment of Pulmonary Fibrosis.
J Med Chem 68: 792-818 (0)
Shenyang Pharmaceutical University
Identification of Novel Organo-Se BTSA-Based Derivatives as Potent, Reversible, and Selective PPARγ Covalent Modulators for Antidiabetic Drug Discovery.
J Med Chem 68: 819-831 (0)
Guangzhou Medical University
Discovery of an Orally Efficacious Pyrazolo[3,4-d]pyrimidine Benzoxaborole as a Potent Inhibitor of Cryptosporidium.
J Med Chem 68: 832-849 (0)
Saint Louis University
In Search for Inhibitors of Human Aldo-Keto Reductase 1B10 (AKR1B10) as Novel Agents to Fight Cancer and Chemoresistance: Current State-of-the-Art and Prospects.
J Med Chem 68: 860-885 (0)
University of Messina
Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects.
J Med Chem 68: 902-914 (0)
Hangzhou Medical College
UBE2N: Hope on the Cancer Front, How to Inhibit This Promising Target Prospect?
J Med Chem 68: 915-928 (0)
Universite de Caen Normandie
Targeting QPCTL: An Emerging Therapeutic Opportunity.
J Med Chem 68: 929-943 (0)
Tongji University Cancer Center
G9a/GLP Modulators: Inhibitors to Degraders.
J Med Chem 68: 953-985 (0)
Osaka University
Fragment-to-Lead Medicinal Chemistry Publications in 2023.
J Med Chem 68: 986-1001 (0)
Astex Pharmaceuticals
Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy.
J Med Chem 68: 1002-1020 (0)
Nanjing University of Chinese Medicine
Recent Progress in the Development of Glucose Transporter (GLUT) Inhibitors.
J Med Chem 68: 1033-1050 (0)
Southern Medical University
In Pursuit of Lead Innovation: Pharmaceutically Important and Distinct Amide-Free Succinate Dehydrogenase Inhibitors.
J Med Chem 68: 1051-1067 (0)
Guizhou University
Current and Emerging Approaches Targeting G9a for the Treatment of Various Diseases.
J Med Chem 68: 1068-1089 (0)
Sichuan University
A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.
J Med Chem 68: 1092-1112 (0)
University of Toronto
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders.
J Med Chem 68: 1113-1133 (0)
University of Michigan
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders.
J Med Chem 68: 1134-1154 (0)
SK Life Science Labs
Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers.
J Med Chem 68: 1155-1178 (0)
University of Michigan
Identification of a Chemical Probe for BLT2 Activation by Scaffold Hopping.
J Med Chem 68: 1195-1221 (0)
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Discovery of 2(1H)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers.
J Med Chem 68: 1222-1244 (0)
China Pharmaceutical University
Discovery of WDR5-MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia.
J Med Chem 68: 1260-1279 (0)
China Pharmaceutical University
Novel Orthosteric/Allosteric Ligands of Cannabinoid Receptors: An Unexpected Pharmacological Profile.
J Med Chem 68: 1280-1299 (0)
University of Pisa
Indolo[3,2-c]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy.
J Med Chem 68: 1300-1315 (0)
China Pharmaceutical University
Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers.
J Med Chem 68: 1344-1364 (0)
University of Chinese Academy of Sciences
Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced Myelosuppression.
J Med Chem 68: 1446-1472 (0)
China Pharmaceutical University
Elucidating Binding Selectivity in Cyclin-Dependent Kinases 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors.
J Med Chem 68: 1499-1510 (0)
Peking University Shenzhen Graduate School
Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer.
J Med Chem 68: 1553-1571 (0)
Guangzhou Institutes of Biomedicine and Health
Repurposing of Agrochemicals as ATTRv Amyloidosis Inhibitors.
J Med Chem 68: 1572-1586 (0)
University of Toyama
Subtle Structural Modifications Spanning from EP4 Antagonism to EP2/EP4 Dual Antagonism: A Novel Class of Thienocyclic-Based Derivatives.
J Med Chem 68: 1587-1607 (0)
East China Normal University
Lanosterol 14α-Demethylase (CYP51)/Heat Shock Protein 90 (Hsp90) Dual Inhibitors for the Treatment of Invasive Candidiasis.
J Med Chem 68: 1668-1681 (0)
Second Military Medical University (Naval Medical University)
Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability.
J Med Chem 68: 1693-1715 (0)
Southern Medical University
Synthesis and Biological Evaluation of Peripheral HTR2A Antagonists for Colorectal Cancer.
J Med Chem 68: 1716-1730 (0)
Korea Research Institute of Chemical Technology
Design, Synthesis, and Pharmacodynamic Evaluation of Highly Selective PARP1 Inhibitors with Brain Penetrance.
J Med Chem 68: 1731-1754 (0)
Sichuan University
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers.
J Med Chem 68: 1772-1792 (0)
Foghorn Therapeutics
TarIKGC: A Target Identification Tool Using Semantics-Enhanced Knowledge Graph Completion with Application to CDK2 Inhibitor Discovery.
J Med Chem 68: 1793-1809 (0)
Sun Yat-sen University
Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Staphylococcus aureus Infection.
J Med Chem 68: 1810-1823 (0)
Shanghai Institute of Materia Medica
Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders.
J Med Chem 68: 1824-1843 (0)
University of Bonn institution
Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction.
J Med Chem 68: 1844-1862 (0)
China Pharmaceutical University
Novel 3-Sulfonamide Dual-Tail Pyrrol-2-one Bridged Molecules as Potent Human Carbonic Anhydrase Isoform Inhibitors: Design, Synthesis, Molecular Modeling Investigation, and Anticancer Activity in MeWo, SK-BR-3, and MG-63 Cell Lines.
J Med Chem 68: 1863-1882 (0)
"Petru Poni" Institute of Macromolecular Chemistry of Romanian Academy
Phenotype-Led Identification of IL-10 Upregulators in Human CD4+ T-cells and Elucidation of Their Pharmacology as Highly Selective CDK8/CDK19 Inhibitors.
J Med Chem 68: 1883-1900 (0)
Medicine Design
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor.
J Med Chem 68: 1924-1939 (0)
Incyte Corporation
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity.
J Med Chem 68: 1940-1955 (0)
Insilico Medicine Shanghai Ltd
Targeting the "Undruggable": Small-Molecule Inhibitors of Proliferating Cell Nuclear Antigen (PCNA) in the Spotlight in Cancer Therapy.
J Med Chem 68: 2058-2088 (0)
Jiangxi University of Chinese Medicine
Recent Developments in 14-3-3 Stabilizers for Regulating Protein-Protein Interactions: An Update.
J Med Chem 68: 2124-2146 (0)
China Pharmaceutical University
Small Molecule Modulators of AMP-Activated Protein Kinase (AMPK) Activity and Their Potential in Cancer Therapy.
J Med Chem 68: 2238-2254 (0)
University of Colorado Anschutz Medical Campus
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.
J Med Chem 68: 2255-2300 (0)
Abbvie
Unlocking the Therapeutic Potential of Natural Products for Alzheimer's Disease.
J Med Chem 68: 2377-2402 (0)
Henan University of Chinese Medicine
Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C.
J Med Chem 68: 2422-2436 (0)
Jacobio Pharmaceuticals Group Co., Ltd.
Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948.
J Med Chem 68: 2466-2482 (0)
Pfizer Inc.
Design, Synthesis and Anti-Inflammatory Evaluation of 3-Substituted 5-Amidobenzoate Derivatives as Novel P2Y14 Receptor Antagonists via Structure-Guided Molecular Hybridization.
J Med Chem 68: 2483-2503 (0)
Zhengzhou University
N-Branched Tricyclic Guanidines as Novel Melanocortin-3 Receptor Agonists and Melanocortin-4 Receptor Antagonists.
J Med Chem 68: 2504-2527 (0)
University of Minnesota
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer.
J Med Chem 68: 2528-2550 (0)
Nankai University
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations.
J Med Chem 68: 2657-2679 (0)
Wuyi University
Discovery of Small Molecules that Bind to Son of Sevenless 2 (SOS2).
J Med Chem 68: 2680-2693 (0)
Vanderbilt University School of Medicine
Design and Synthesis of Hederagenin Derivatives for the Treatment of Sepsis by Targeting TAK1 and Regulating the TAK1-NF-κB/MAPK Signaling.
J Med Chem 68: 2694-2719 (0)
Yantai University
Discovery of Novel RNA Demethylase FTO Inhibitors Featuring an Acylhydrazone Scaffold with Potent Antileukemia Activity.
J Med Chem 68: 2742-2763 (0)
University of Chinese Academy of Sciences
Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies.
J Med Chem 68: 2779-2803 (0)
Taipei Medical University
Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy.
J Med Chem 68: 2815-2839 (0)
Sichuan University
Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer Agents.
J Med Chem 68: 2849-2868 (0)
Central University of Punjab
Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment.
J Med Chem 68: 2869-2889 (0)
Sichuan University
Strategic Mutations in Designer Native Peptides Combat NLRP3 Inflammasome Activation in Neurodegenerative Disorders.
J Med Chem 68: 2890-2902 (0)
Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR)
Structure-Activity Relationship Studies of DNA Methyltransferase 1 Monovalent Degraders.
J Med Chem 68: 2903-2919 (0)
Icahn School of Medicine at Mount Sinai
Design, Synthesis, and Biological Evaluation of 1,3,4-Thiadiazole Derivatives as Novel Potent Peptide Deformylase Inhibitors for Combating Drug-Resistant Gram-Positive and -Negative Bacteria.
J Med Chem 68: 2942-2962 (0)
Henan Normal University
Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation.
J Med Chem 68: 2963-2980 (0)
China Pharmaceutical University
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.
J Med Chem 68: 2981-3003 (0)
Epics Therapeutics SA
Discovery of Metabolic Reprogramming 2-Quinolones as Effective Antimicrobials for MRSA-Infected Wound Therapy.
J Med Chem 68: 3004-3019 (0)
Jilin University
Structure-Based Virtual Screening Identifies 2-Arylthiazole-4-Carboxylic Acids as a Novel Class of Nanomolar Affinity Ligands for the CaMKIIα Hub Domain.
J Med Chem 68: 3031-3047 (0)
University of Copenhagen
Discovery of Novel Hydrazide-Based HDAC3 Inhibitors as Epigenetic Immunomodulators for Cancer Immunotherapy.
J Med Chem 68: 3048-3064 (0)
Southern Medical University
Metabolically Stable Adenylation Inhibitors of Biotin Protein Ligase as Antibacterial Agents.
J Med Chem 68: 3065-3087 (0)
University of Minnesota
Sulfonium Moieties as Ammonium Bioisosteres: Novel Ligands for the Alpha7 Nicotinic Acetylcholine Receptor.
J Med Chem 68: 3157-3179 (0)
University of Milan
Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy.
J Med Chem 68: 3212-3237 (0)
Gannan Medical University
Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.
J Med Chem 68: 3238-3259 (0)
TU Dortmund University and Drug Discovery Hub Dortmund (DDHD)
Design, Synthesis, and Biological Evaluation of Thieno[3,2-d]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors.
J Med Chem 68: 3260-3281 (0)
Chongqing University of Arts and Sciences
Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve.
J Med Chem 68: 3282-3308 (0)
University of North Carolina at Chapel Hill
Development of a Highly Selective Ferroptosis Inducer Targeting GPX4 with 2-Ethynylthiazole-4-carboxamide as Electrophilic Warhead.
J Med Chem 68: 3309-3323 (0)
Hainan University
Effects of Heparan Sulfate Trisaccharide Containing Oleanolic Acid in Attenuating Hyperphosphorylated Tau-Induced Cell Dysfunction Associated with Alzheimer's Disease.
J Med Chem 68: 3356-3372 (0)
Wayne State University
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists.
J Med Chem 68: 3386-3408 (0)
China Pharmaceutical University
Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists.
J Med Chem 68: 3445-3459 (0)
Zhejiang University
Discovery of Novel Spirocyclic MAT2A Inhibitors Demonstrating High In Vivo Efficacy in MTAP-Null Xenograft Models.
J Med Chem 68: 3480-3494 (0)
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Network-Based Drug Optimization toward the Treatment of Parkinson's Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation.
J Med Chem 68: 3495-3517 (0)
Instituto de Quimica Medica
Design of (R)-3-(5-Thienyl)carboxamido-2-aminopropanoic Acid Derivatives as Novel NMDA Receptor Glycine Site Agonists: Variation in Molecular Geometry to Improve Potency and Augment GluN2 Subunit-Specific Activity.
J Med Chem 68: 3572-3590 (0)
University of Copenhagen
Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity.
J Med Chem 68: 3626-3652 (0)
Eberhard Karls University Tubingen
Transition State Analogs of Human DNPH1 Reveal Two Electrophile Migration Mechanisms.
J Med Chem 68: 3653-3672 (0)
Albert Einstein College of Medicine
Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors.
J Med Chem 68: 3673-3699 (0)
Chinese Academy of Sciences
Novel N-(3-(1-(4-sulfamoylphenyl)triazol-4-yl)phenyl)benzamide Derivatives as Potent Carbonic Anhydrase Inhibitors with Broad-Spectrum Anticancer Activity: Leveraging Tail and Dual-Tail Approaches.
J Med Chem 68: 3764-3781 (0)
Mansoura University
Design, Synthesis, and Pharmacological Evaluation of Nonsteroidal Tricyclic Ligands as Modulators of GABAA Receptors.
J Med Chem 68: 3795-3813 (0)
University of Copenhagen
Design, Synthesis, and Evaluation of Selective PDE4 Inhibitors for the Therapy of Pulmonary Injury.
J Med Chem 68: 3837-3857 (0)
Guangdong Academy of Sciences
Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance.
J Med Chem 68: 3886-3899 (0)
Insilico Medicine Shanghai Ltd
Mitophagy in Neurodegenerative Diseases: Mechanisms of Action and the Advances of Drug Discovery.
J Med Chem 68: 3970-3994 (0)
Sichuan Universit
A Medicinal Chemistry Perspective on Protein Tyrosine Phosphatase Nonreceptor Type 2 in Tumor Immunology.
J Med Chem 68: 3995-4021 (0)
Fudan University
Structural Chemistry of Helicase Inhibition.
J Med Chem 68: 4022-4039 (0)
University of Toronto
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
J Med Chem 68: 4040-4052 (0)
Purdue University
Negative Allosteric Modulators of A2AR: A New Weapon for Cancer Immunotherapy?
J Med Chem 68: 4053-4055 (0)
University of Modena and Reggio Emilia
Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer Immunotherapies.
J Med Chem 68: 4059-4078 (0)
University of Geneva
Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2.
J Med Chem 68: 4101-4132 (0)
Henan Normal University
Discovery of a Novel Selective and Cell-Active N6-Methyladenosine RNA Demethylase ALKBH5 Inhibitor.
J Med Chem 68: 4133-4147 (0)
Sun Yat-sen University
Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors.
J Med Chem 68: 4148-4167 (0)
Insilico Medicine Shanghai Ltd
Discovery of New Nanomolar Selective IRAP Inhibitors.
J Med Chem 68: 4168-4195 (0)
Univ. Lille
Design, Synthesis, and Mechanism Study of Novel BMX Inhibitors Based on the Core of 1,3,5-Triazin-2-Amine for the Treatment of Gastric Carcinoma.
J Med Chem 68: 4196-4216 (0)
Zhengzhou University
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design.
J Med Chem 68: 4217-4236 (0)
Tango Therapeutics
Discovery of Diphenyl Ether Derivatives as Novel BKCa Channel Activators: Structure-Activity Relationship, Cryo-EM Complex Structures, and In Vivo Animal Studies.
J Med Chem 68: 4259-4286 (0)
Gwangju Institute of Science and Technology
Harnessing the Magic Methyl Effect: Discovery of CLPP-2068 as a Novel HsClpP Activator for the Treatment of Diffuse Large B-Cell Lymphoma.
J Med Chem 68: 4287-4307 (0)
Shanghai Institute of Materia Medica
A Fluorescent Probe Enables the Discovery of Improved Antagonists Targeting the Intracellular Allosteric Site of the Chemokine Receptor CCR7.
J Med Chem 68: 4308-4333 (0)
University of Bonn
Switching Roles─Exploring Concentration-Dependent Agonistic versus Antagonistic Behavior of Integrin Ligands.
J Med Chem 68: 4334-4351 (0)
TUM University Hospital
Opto-Epigenetic Regulation of Histone Arginine Asymmetric Dimethylation via Type I Protein Arginine Methyltransferase Inhibition.
J Med Chem 68: 4373-4381 (0)
The University of Hong Kong
Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties.
J Med Chem 68: 4426-4452 (0)
University of Bonn
Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity.
J Med Chem 68: 4477-4497 (0)
Hefei University of Technology
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.
J Med Chem 68: 4582-4595 (0)
AstraZeneca
Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector.
J Med Chem 68: 4596-4618 (0)
Istituto Italiano di Tecnologia (IIT)
Design, Synthesis, and Characterization of GluN2A Negative Allosteric Modulators Suitable for In Vivo Exploration.
J Med Chem 68: 4672-4693 (0)
Janssen Research & Development
Property-Based Design of Xanthine Derivatives as Potent and Orally Available TRPC4/5 Inhibitors for Depression and Anxiety.
J Med Chem 68: 4694-4720 (0)
Shanghai Institute of Materia Medica
Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 Synthase.
J Med Chem 68: 4721-4742 (0)
Novartis Pharma AG
Design, Synthesis, and Activity Evaluation of Novel Bifenamide Dual-Target Antibacterial Inhibitors and Carrier Based on Infectious Microenvironment.
J Med Chem 68: 4743-4762 (0)
Liaocheng University
BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.
J Med Chem 68: 4763-4786 (0)
University of Ioannina
Identification of Structurally Novel KRASG12C Inhibitors through Covalent DNA-Encoded Library Screening.
J Med Chem 68: 4801-4817 (0)
Amgen Research
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists.
J Med Chem 68: 4818-4828 (0)
Pfizer Inc.
A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene Expression.
J Med Chem 68: 4829-4847 (0)
Ludwig-Maximilians-Universite
Discovery of Potent and Brain-Penetrant Bicyclic NLRP3 Inhibitors with Peripheral and Central In Vivo Activity.
J Med Chem 68: 4848-4887 (0)
A Johnson & Johnson Company
Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists.
J Med Chem 68: 4888-4907 (0)
University of Bonn
Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting.
J Med Chem 68: 4929-4950 (0)
China Pharmaceutical University
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC).
J Med Chem 68: 4961-4987 (0)
Northwestern University
Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities.
J Med Chem 68: 5024-5054 (0)
Gannan Medical University
MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.
J Med Chem 68: 5075-5096 (0)
China Pharmaceutical University
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.
J Med Chem 68: 5097-5119 (0)
Tango Therapeutics
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.
J Med Chem 68: 5125-5151 (0)
University of Michigan
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
J Med Chem 68: 5152-5169 (0)
Gilead Sciences Inc.
ONC201-Derived Tetrahydropyridopyrimidindiones as Powerful ClpP Protease Activators to Tackle Diffuse Midline Glioma.
J Med Chem 68: 5190-5210 (0)
University of Bari Aldo Moro
Engineered Cyclotide Blocks Neuronal Excitotoxicity.
J Med Chem 68: 5211-5221 (0)
Macquarie University
Discovery, Synthesis, and Activity Evaluation of Novel Small-Molecule Inhibitors Targeting VISTA for Cancer Immunotherapy.
J Med Chem 68: 5222-5237 (0)
China Pharmaceutical University
Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects.
J Med Chem 68: 5238-5256 (0)
Peking University
Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.
J Med Chem 68: 5257-5274 (0)
University of Chinese Academy of Sciences
Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor.
J Med Chem 68: 5292-5311 (0)
Chinese Academy of Medical Sciences & Peking Union Medical College
Design and Synthesis of Novel Deazapurine DNMT 1 Inhibitors with In Vivo Efficacy in DLBCL.
J Med Chem 68: 5333-5357 (0)
Sichuan University
Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer.
J Med Chem 68: 5358-5381 (0)
Fudan University
Novel Hypochlorous Acid-Activated Near-Infrared Probe Monitors the Dynamic Changes of Myeloperoxidase Activity in Ischemic Brain.
J Med Chem 68: 5382-5399 (0)
Nanjing Medical University
Structural Optimization of Covalent Inhibitors for Deubiquitinase ChlaDUB1 of Chlamydia trachomatis as Antibiotic Agents.
J Med Chem 68: 5400-5425 (0)
Julius-Maximilians-Universitat Wurzburg (JMU)
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy.
J Med Chem 68: 5426-5454 (0)
Gannan Medical University
Orally Bioavailable and Site-Selective Covalent STING Inhibitor Derived from a Macrocyclic Marine Diterpenoid.
J Med Chem 68: 5471-5487 (0)
National Health Research Institutes
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
J Med Chem 68: 5529-5550 (0)
IFM Therapeutics GmbH
Discovery of Novel Oxazolo[4,3-f]purine Derivatives as Antitumor Agents through PPIA Interaction.
J Med Chem 68: 5573-5596 (0)
Henan Normal University
Selective Degradation of TEADs by a PROTAC Molecule Exhibited Robust Anticancer Efficacy In Vitro and In Vivo.
J Med Chem 68: 5616-5640 (0)
Shanghai Institute of Materia Medica
Discovery of Novel Pyrrolo[2,3-b]pyridine-Based CSF-1R Inhibitors with Demonstrated Efficacy against Patient-Derived Colorectal Cancer Organoids.
J Med Chem 68: 5655-5674 (0)
Nanjing University of Chinese Medicine
Multi-Water Bridges Enable Design of BET BD1-Selective Inhibitors for Pancreatic Cancer Therapy.
J Med Chem 68: 5719-5735 (0)
China Pharmaceutical University
Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia.
J Med Chem 68: 5736-5759 (0)
Chinese Academy of Medical Sciences and Peking Union Medical College
Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors.
J Med Chem 68: 5760-5773 (0)
Michigan State University
Discovery of Isobenzofuran-1(3H)-one Derivatives as Selective TREK-1 Inhibitors with In Vitro and In Vivo Neuroprotective Effects.
J Med Chem 68: 5804-5823 (0)
Chinese Academy of Medical Sciences and Peking Union Medical College
Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia.
J Med Chem 68: 5824-5844 (0)
Northwestern University
Design, Synthesis, and Pharmacological Evaluation of Quinazoline and Quinoline Derivatives as Potent ENPP1 Inhibitors for Cancer Immunotherapy.
J Med Chem 68: 5856-5873 (0)
Shanghai Jiao Tong University
Sertraline and Astemizole Enhance the Deubiquitinase Activity of USP7 by Binding to Its Switching Loop Region.
J Med Chem 68: 5874-5890 (0)
Shanghai Institute of Materia Medica
Discovery of Novel 2,4,5-Trisubstituted Pyrimidine Derivatives as Potent and Selective FGFR Inhibitors against Gatekeeper Mutants for the Treatment of NSCLC.
J Med Chem 68: 5907-5925 (0)
Wenzhou Medical University
Structure and Dynamics of Macrophage Infectivity Potentiator Proteins from Pathogenic Bacteria and Protozoans Bound to Fluorinated Pipecolic Acid Inhibitors.
J Med Chem 68: 5926-5941 (0)
Friedrich Schiller University Jena
MrgX2-Targeting Ligand Screen for Antipseudoallergic Agents by Immobilized His-Tag-Fused Protein Technology.
J Med Chem 68: 5942-5953 (0)
Xi'an Jiaotong University
Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers.
J Med Chem 68: 5954-5972 (0)
Zhengzhou University
An Amazing 30-Year Journey around the DABO Family: A Medicinal Chemistry Lesson on a Versatile Class of Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.
J Med Chem 68: 5993-6026 (0)
Sapienza University of Rome
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.
J Med Chem 68: 6064-6083 (0)
Revolution Medicines, Inc.
Discovery of BT-114143, a Novel and Potent Phosphoric Acid-Containing Small-Molecule Plasminogen Activation Inhibitor for Hyperfibrinolysis.
J Med Chem 68: 6084-6099 (0)
ScinnoHub Pharmaceutical Co., Ltd.
Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH.
J Med Chem 68: 6104-6107 (0)
The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning
Discovery and Preclinical Characterization of Fulacimstat (BAY 1142524), a Potent and Selective Chymase Inhibitor As a New Profibrinolytic Approach for Safe Thrombus Resolution.
J Med Chem 68: 6108-6126 (0)
Bayer AG
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease.
J Med Chem 68: 6127-6148 (0)
Guangdong Pharmaceutical University
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability.
J Med Chem 68: 6165-6177 (0)
University of Toronto Mississauga
AI-Driven Discovery of Highly Specific and Efficacious hCES2A Inhibitors for Ameliorating Irinotecan-Triggered Gut Toxicity.
J Med Chem 68: 6252-6269 (0)
Hainan University
Discovery of 5-Phenylthiazol-2-amine Derivatives as Novel PI4KIIIβ Inhibitors with Efficacious Antitumor Activity by Inhibiting the PI3K/AKT Axis.
J Med Chem 68: 6270-6291 (0)
China Pharmaceutical University
Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor.
J Med Chem 68: 6292-6311 (0)
Sapienza University of Rome
Structure-Based Development of 3,4-Fused Tricyclic Benzofuran Derivatives as Polyketide Synthase 13 Inhibitors with Negligible hERG Inhibition.
J Med Chem 68: 6312-6327 (0)
East China Normal University
Discovery of Novel, Potent, Orally Bioavailable and Efficacious, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Hematopoietic Stem Cell Mobilization.
J Med Chem 68: 6386-6406 (0)
FibroGen Inc.
DNA-Encoded Library Screen Identifies Novel Series of Respiratory Syncytial Virus Polymerase Inhibitors.
J Med Chem 68: 6407-6430 (0)
Johnson & Johnson Company
Synthesis and Biological Evaluation of Peripheral 5HT2B Antagonists for Liver Fibrosis.
J Med Chem 68: 6493-6506 (0)
Jeonbuk National University Medical School
From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy.
J Med Chem 68: 6534-6557 (0)
Amgen Inc
Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy.
J Med Chem 68: 6558-6575 (0)
Roche Pharma Research and Early Development
Size-Dependent Target Engagement of Covalent Probes.
J Med Chem 68: 6616-6632 (0)
HUN-REN Research Centre for Natural Sciences
Discovery and Optimization of Novel Apo-IDO1 Inhibitors by a Pharmacophore-Based Structural Simplification Strategy.
J Med Chem 68: 6633-6655 (0)
China Pharmaceutical University
UNC9426, a Potent and Orally Bioavailable TYRO3-Specific Inhibitor.
J Med Chem 68: 6665-6682 (0)
University of North Carolina at Chapel Hill
The Heterogeneous Kinetic Origins of the Binding Properties of Orthosteric Ligands at Heteromeric Nicotinic Acetylcholine Receptors.
J Med Chem 68: 6683-6697 (0)
University of Copenhagen
Designing Macrocyclic Kinase Inhibitors Using Macrocycle Scaffold Hopping with Reinforced Learning (Macro-Hop).
J Med Chem 68: 6698-6717 (0)
Jinan University
Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition.
J Med Chem 68: 6718-6734 (0)
Shanghai Institute of Organic Chemistry
Discovery of New Azaindole Metallo-Deubiquitinase CSN5 Inhibitors.
J Med Chem 68: 6748-6765 (0)
Xihua University
Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency.
J Med Chem 68: 6766-6788 (0)
Changchun Genescience Pharma
Structure-Based Optimization of Moracin M as Potent and Selective PDE4 Inhibitors with Antipsoriasis Effects.
J Med Chem 68: 6789-6803 (0)
Hainan University
Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH Treatments.
J Med Chem 68: 6815-6831 (0)
University of Edinburgh
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
J Med Chem 68: 6932-6954 (0)
Amgen Inc.
Towards P2X4 Positron Emission Tomography Tracing.
J Med Chem 68: 6961-6964 (0)
University of Trieste
Naphtho[1,2-b][1,4]diazepinedione-Based P2X4 Receptor Antagonists from Structure-Activity Relationship Studies toward PET Tracer Development.
J Med Chem 68: 6965-7002 (0)
University of Muenster
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease.
J Med Chem 68: 7003-7030 (0)
Pfizer Inc.
Potent and Selective Human Constitutive Androstane Receptor Activator DL5055 Facilitates Cyclophosphamide-Based Chemotherapies.
J Med Chem 68: 7044-7061 (0)
University of Maryland
Discovery of Conformationally Constrained Dihydro Benzo-Indole Derivatives as Metallo-β-Lactamase Inhibitors to Tackle Multidrug-Resistant Bacterial Infections.
J Med Chem 68: 7062-7081 (0)
CSIR-Institute of Microbial Technology
Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT2C Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer's Disease-Related Psychosis.
J Med Chem 68: 7082-7105 (0)
Yantai University
Discovery of HM-279, a Potent Inhibitor of ALK5 for Improving Therapeutic Efficacy of Cancer Immunotherapy.
J Med Chem 68: 7106-7118 (0)
Carna Biosciences, Inc.
From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants.
J Med Chem 68: 7119-7136 (0)
University of Sherbrooke
Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies.
J Med Chem 68: 7180-7196 (0)
University of Tuebingen
Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization.
J Med Chem 68: 7263-7279 (0)
University of Oulu
Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction.
J Med Chem 68: 7291-7312 (0)
Capital Medical University
Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma.
J Med Chem 68: 7367-7389 (0)
China Pharmaceutical University
From Bones to Bugs: Structure-Based Development of Raloxifene-Derived Pathoblockers That Inhibit Pyocyanin Production in Pseudomonas aeruginosa.
J Med Chem 68: 7390-7420 (0)
Technische Universitat Braunschweig
Discovery of the 2,3-Dihydrobenzopyrane-4-one as a Potent FTO Inhibitor against Obesity-Related Metabolic Diseases.
J Med Chem 68: 7421-7440 (0)
Anhui Medical University
Development of Tricyclic 4,5-Dihydro-3H-pyrrolo[2,3-c]quinolin-4-ones as Potent Autotaxin Inhibitors for Pulmonary Fibrosis Treatment In Vivo.
J Med Chem 68: 7476-7498 (0)
Shenyang Pharmaceutical University
Discovery of c-Kit as a New Therapeutic Target in LPS-Induced Acute Lung Injury through Novel Phenylamide Derivative D9.
J Med Chem 68: 7499-7517 (0)
Wenzhou Medical University
Discovery of Novel SIK2/3 Inhibitors for the Potential Treatment of MEF2C+ Acute Myeloid Leukemia (AML).
J Med Chem 68: 7518-7538 (0)
Insilico Medicine Shanghai Ltd.
Discovery of Potent and Balanced Dual RIPK2 and 3 Inhibitors as a New Strategy for the Treatment of Inflammatory Bowel Diseases.
J Med Chem 68: 7539-7559 (0)
Anhui Medical University
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model.
J Med Chem 68: 7560-7578 (0)
China Pharmaceutical University
Chemoproteomic Profiling of C. albicans for Characterization of Antifungal Kinase Inhibitors.
J Med Chem 68: 7615-7629 (0)
University of North Carolina at Chapel Hill
Indolizine Derivatives Inhibit TRPM2 and Protect against Ischemic Brain Injury with an Extended Treatment Window.
J Med Chem 68: 7642-7661 (0)
Zhejiang University
Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C-Domain-Selective/Neprilysin Inhibitors.
J Med Chem 68: 7720-7736 (0)
University of Bath
PaAP-Activatable NIR Probe for Diagnosing, Imaging, and Discovering Small-Molecule Therapeutics against Implant-Associated Biofilm Infections.
J Med Chem 68: 7827-7838 (0)
Chinese Academy of Medical Sciences & Peking Union Medical College
Tertiary Alcohol: Reaping the Benefits but Minimizing the Drawbacks of Hydroxy Groups in Drug Discovery.
J Med Chem 68: 7889-7913 (0)
Takeda Pharmaceuticals
Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies.
J Med Chem 68: 7914-7931 (0)
Zhengzhou University
Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia.
J Med Chem 68: 7955-7972 (0)
Sunshine Lake Pharma Company, Ltd.
Novel Spiro-Barbiturates Can Reverse the Action of General Anesthetics on the GABAAR.
J Med Chem 68: 8025-8045 (0)
University of Illinois Chicago
Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.
J Med Chem 68: 8046-8064 (0)
Southern Medical University
Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids.
J Med Chem 68: 8065-8090 (0)
Monash University (Parkville Campus)
Efficacy and Toxicity Analysis of Selective BET Bromodomain Inhibitors in Models of Inflammatory Liver Disease.
J Med Chem 68: 8091-8105 (0)
University of Minnesota
Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.
J Med Chem 68: 8106-8123 (0)
Hefei Institutes of Physical Science
HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation.
J Med Chem 68: 8124-8142 (0)
Shandong University
Selective Inhibition of Rat α7 Nicotinic Acetylcholine Receptors by LvID, a Newly Characterized α4/7-Conotoxin from Conus lividus.
J Med Chem 68: 8163-8173 (0)
Zhejiang University
PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation.
J Med Chem 68: 8190-8207 (0)
Fudan University
Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer.
J Med Chem 68: 8244-8268 (0)
China Pharmaceutical University
Accelerating the Hit-To-Lead Optimization of a SARS-CoV-2 Mpro Inhibitor Series by Combining High-Throughput Medicinal Chemistry and Computational Simulations.
J Med Chem 68: 8269-8294 (0)
Idorsia Pharmaceuticals Limited
Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer.
J Med Chem 68: 8330-8345 (0)
China Pharmaceutical University
Lead Optimization of Positive Allosteric KV7.2/3 Channel Modulators toward Improved Balance of Lipophilicity and Aqueous Solubility.
J Med Chem 68: 8377-8399 (0)
University of Greifswald
Discovery of Novel TYRO3/MERTK Dual Inhibitors.
J Med Chem 68: 8455-8470 (0)
University of North Carolina at Chapel Hill
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy.
J Med Chem 68: 8497-8515 (0)
China Innovation Center of Roche
Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader.
J Med Chem 68: 8543-8563 (0)
Icahn School of Medicine at Mount Sinai
Deuteration Strategy-Inspired Design of Novel Diarylpyrimidine Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Efficacy, Selectivity, and Druggability.
J Med Chem 68: 8564-8577 (0)
Fudan University
Identification of Novel Cyclobutane-Based Derivatives as Potent Acetyl-CoA Carboxylase Allosteric Inhibitors for Nonalcoholic Steatohepatitis Drug Discovery.
J Med Chem 68: 8578-8599 (0)
Nanjing Sanhome Pharmaceutical Co. Ltd.
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.
J Med Chem 68: 8634-8647 (0)
Icahn School Of Medicine At Mount Sinai
Structure-Based Discovery Targeting GSK-3α Reveals Potent Nanomolar Selective 4-Phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine Inhibitor with Promising Glioblastoma and CNS-Active Potential in Cellular Models.
J Med Chem 68: 8679-8693 (0)
University of Central Lancashire
Development of Squaramides as Allosteric Modulators of the CB1 Receptor: Synthesis, Computational Studies, Biological Characterization, and Effects against Cocaine-Induced Behavioral Sensitization and Reinstatement in Rats.
J Med Chem 68: 8694-8712 (0)
Research Triangle Institute
Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis.
J Med Chem 68: 8713-8728 (0)
Phenex Pharmaceuticals AG
Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related Diseases.
J Med Chem 68: 8729-8767 (0)
Shenyang Pharmaceutical University
Bifunctional Inhibition of Botulinum Neurotoxin A Protease: Unexpected Active Site Inhibition Enhances Covalent Targeting of an Allosteric Site.
J Med Chem 68: 8796-8816 (0)
The Scripps Research Institute
Design, Synthesis, and Biological Evaluation of Pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Potent and Orally Available Noncovalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
J Med Chem 68: 8841-8860 (0)
East China University of Science and Technology
Rational Design of Methylene Blue-Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation.
J Med Chem 68: 8861-8872 (0)
Guizhou University
Shooting an Arrow against Convulsion: Novel Triazole-Grafted Benzenesulfonamide Derivatives as Carbonic Anhydrase II and VII Inhibitors.
J Med Chem 68: 8873-8893 (0)
Horus University-Egypt
Discovery of Potent STING Inhibitors Bearing a Difluorobenzodioxol Structural Motif as Potent Anti-Inflammatory Agents.
J Med Chem 68: 8907-8932 (0)
Shanghai Jiao Tong University
Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4.
J Med Chem 68: 8933-8966 (0)
The University of Melbourne
Discovery of Phenylacylpiperidine as Novel sEH Inhibitors through Scaffold Hopping of Natural Stilbene.
J Med Chem 68: 8980-9013 (0)
Beijing Institute of Technology
Drug-like Antagonists of P2Y Receptor Subtypes: An Update.
J Med Chem 68: 9057-9083 (0)
University of Nottingham
Inverse Agonists of Peroxisome Proliferator-Activated Receptor Gamma: Advances and Prospects in Cancer Treatment.
J Med Chem 68: 9084-9100 (0)
Shenyang Pharmaceutical University
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of Glioblastoma.
J Med Chem 68: 9101-9125 (0)
BenevolentAI
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
J Med Chem 68: 9129-9161 (0)
CRUK Scotland Institute
Exploring Simple Drug Scaffolds from the Generated Database Chemical Space Reveals a Chiral Bicyclic Azepane with Potent Neuropharmacology.
J Med Chem 68: 9176-9201 (0)
University of Bern
Discovery and Evaluation of Active Site-Directed, Potent, and Selective Sulfophenyl Acetic Amide-Based Inhibitors for the Laforin Phosphatase.
J Med Chem 68: 9220-9240 (0)
Purdue University
Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells.
J Med Chem 68: 9241-9259 (0)
Shanghai University
Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases.
J Med Chem 68: 9279-9302 (0)
Ocean University of China
Thienopyrimidinone Derivatives as a GluN2B/C/D Biased, Positive Allosteric Modulator of the N-Methyl-d-Aspartate Receptor.
J Med Chem 68: 9303-9322 (0)
Emory University
Synthesis of 5,9- and 5,8-Diaminoalkoxy Substituted Benzophenanthridinone Analogues as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors and Their Radiosensitizing Activity.
J Med Chem 68: 9323-9340 (0)
Sun Yat-sen University
Design, Synthesis, and Biological Evaluation of Selective STING Synergists That Enhance cGAMP-STING Pathway Activation without Inherent Agonist Activity.
J Med Chem 68: 9407-9430 (0)
Beijing Institute of Pharmacology and Toxicology
Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.
J Med Chem 68: 9431-9445 (0)
The Hebrew University of Jerusalem
Discovery and Optimization of a Covalent AKR1C3 Inhibitor.
J Med Chem 68: 9465-9478 (0)
University of Texas at Austin
Challenging the "Undruggable"─Targeting STAT3 but Identifying Potent TrkA-Targeted Inhibitors.
J Med Chem 68: 9501-9524 (0)
University of British Columbia
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9.
J Med Chem 68: 9537-9554 (0)
Accent Therapeutics, Inc.
On-Resin Assembly of Macrocyclic Inhibitors of Cryptococcus neoformans May1: A Pathway to Potent Antifungal Agents.
J Med Chem 68: 9623-9637 (0)
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.
J Med Chem 68: 9638-9660 (0)
University of Sussex
Toward Dual-Target Glycomimetics against Two Bacterial Lectins to Fight Pseudomonas aeruginosa-Burkholderia cenocepacia Infections: A Biophysical Study.
J Med Chem 68: 9681-9693 (0)
Universite degli Studi di Milano
Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis.
J Med Chem 68: 9755-9776 (0)
China Pharmaceutical University
Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase.
J Med Chem 68: 9777-9798 (0)
University of Oxford
Discovery of 3-(Fluoro-imidazolyl)pyridazine Derivatives as Potent STING Agonists with Antitumor Activity.
J Med Chem 68: 9864-9885 (0)
Chinese Academy of Sciences
Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity.
J Med Chem 68: 9886-9905 (0)
China Pharmaceutical University
Bardoxolone Derivatives as Novel Pseudo-Natural Necroptosis Inhibitors by Destabilizing HSP90 Client Proteins.
J Med Chem 68: 9906-9925 (0)
Second Military Medical University
Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3-d]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor.
J Med Chem 68: 9926-9946 (0)
Duke University School of Medicine
Design, Synthesis, and Biological Evaluation of Novel Activators of Human Caseinolytic Protease P with a Pyrazololactam Scaffold.
J Med Chem 68: 9984-10007 (0)
China Pharmaceutical University
Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety.
J Med Chem 68: 10008-10030 (0)
Shandong First Medical University & Shandong Academy of Medical Sciences
New Insights into the French Paradox: Free Radical Scavenging by Resveratrol Yields Cardiovascular Protective Metabolites.
J Med Chem 68: 10031-10047 (0)
University of Szeged
Discovery of P11-2: A Potent First-in-Class MNK1-Targeting PROTAC Degrader for the Treatment of Cancer.
J Med Chem 68: 10092-10110 (0)
Guangdong Pharmaceutical University
Real Way to Target Gram-Negative Pathogens: Discovery of a Novel Helicobacter pylori Antibiotic Class.
J Med Chem 68: 10128-10138 (0)
The University of Iowa College of Pharmacy
PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer.
J Med Chem 68: 10139-10155 (0)
Ocean University of China
Identification of a RANKL/TNF-α Dual-Inhibitor as a Potential Disease-Modifying Agent for the Treatment of Knee Osteoarthritis.
J Med Chem 68: 10216-10237 (0)
ShanghaiTech University
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC.
J Med Chem 68: 10238-10254 (0)
Risen (Shanghai) Pharma Tech Co., Ltd.
Rational Design of Dual Degraders by Incorporating Molecular Glue Structural Features into PROTAC Degraders.
J Med Chem 68: 10268-10298 (0)
Ocean University of China
De Novo 3-(Phenylcarbamoyl) Benzoate Analogues: Efficacy against Multidrug-Resistant S. aureus and Elucidation of the Biodistribution Profile.
J Med Chem 68: 10329-10345 (0)
Indian Institute of Technology Kanpur
AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors.
J Med Chem 68: 10346-10364 (0)
Instituto de Ciencias Matemeticas (ICMAT-CSIC)
Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines.
J Med Chem 68: 10365-10383 (0)
Sun Yat-Sen University
A First-in-Class Hepatocyte Nuclear Factor 4 Agonist.
J Med Chem 68: 10410-10424 (0)
Goethe University Frankfurt
Structure-Guided Optimization of 2-Aminoquinazoline Hematopoietic Progenitor Kinase 1 Inhibitors for Improved Oral Bioavailability and Synergistic Antitumor Immunity.
J Med Chem 68: 10439-10460 (0)
China Pharmaceutical University
A Perspective on the Strategic Application of Deconstruction-Reconstruction in Drug Discovery.
J Med Chem 68: 10520-10539 (0)
AstraZeneca
Harder than Metal: Challenging Antimicrobial Resistance with Metallo-β-lactamase Inhibitors.
J Med Chem 68: 10556-10576 (0)
University of Naples Federico II
Diazepine Agonists of the 5-HT2C Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352).
J Med Chem 68: 10599-10618 (0)
Arena Pharmaceuticals
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.
J Med Chem 68: 10631-10647 (0)
Repare Therapeutics, Inc.
Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer.
J Med Chem 68: 10648-10662 (0)
Kinnate Biopharma Inc.
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy.
J Med Chem 68: 10663-10676 (0)
Arcus Biosciences, Inc.
Development of Novel Phthalazinone-Triazole Hybrids as Potential Antidiabetic Agents Targeting GLUT4 Translocation in Skeletal Muscle.
J Med Chem 68: 10722-10737 (0)
CSIR-Central Drug Research Institute BS
Novel Carbamate-Based o-aminobenzamide Derivatives as Potent Antigastric Carcinoma Agents via Disrupting NAD+ Salvage Synthesis.
J Med Chem 68: 10738-10756 (0)
University of South China
Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidylinositol 4-Kinase Beta and cGMP-Dependent Protein Kinase Inhibitor, for Malaria.
J Med Chem 68: 10757-10770 (0)
University of Cape Town
Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix.
J Med Chem 68: 10877-10896 (0)
National Health Research Institutes
Design, Synthesis, and Biological Evaluation of 4-(Difluoromethyl)-1H-imidazole-5-carboxylic Acids/4-(3-Cyanophenoxy)pyrimidine-5-carboxylic Acids as P2Y1 Receptor Antagonists for Ischemic Stroke Treatment.
J Med Chem 68: 10930-10952 (0)
Shenyang Pharmaceutical University
Design of Potent Small-Molecule Stimulator of Interferon Gene Inhibitor and Stimulator of Interferon Gene Mutant-Specific Degrader.
J Med Chem 68: 11100-11126 (0)
University of Michigan
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity.
J Med Chem 68: 11127-11148 (0)
Guangdong Pharmaceutical University
Similar Binding Mode of a 5-Sulfonylthiouracil Derivative Antagonist at Chemerin Receptors CMKLR1 and GPR1.
J Med Chem 68: 11149-11173 (0)
Leipzig University
Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol Derivatives as ROR1 Inhibitors with Improved Activity and Selectivity.
J Med Chem 68: 11188-11216 (0)
Sichuan University
Design of an Oral STING Agonist through Intramolecular Hydrogen Bond Ring Mimicking to Achieve Complete Tumor Regression.
J Med Chem 68: 11365-11385 (0)
University of Michigan
Lysine-Targeted Covalent Strategy Leading to the Discovery of Novel Potent PROTAC-Based PI3Kδ Degraders.
J Med Chem 68: 11437-11467 (0)
Xi'an Jiaotong University
Structural Optimization of Next-Generation TRK Inhibitors against Acquired Drug Resistance Mutations for the Treatment of Solid Tumors.
J Med Chem 68: 11484-11501 (0)
Shanghai Institute of Materia Medica
Discovery and Administration Optimization of Novel Selective CDK9 Inhibitor, 1-7a-B1, for Improved Pharmacokinetics and Antitumor Efficacy In Vivo.
J Med Chem 68: 11586-11605 (0)
Shenyang Pharmaceutical University
Design, Synthesis, and Biological Evaluation of New PDE4 Inhibitors for the Treatment of Pressure Ulcers.
J Med Chem 68: 11628-11647 (0)
Wuyi University
Discovery of a Potent FLT3 Inhibitor (E)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 Mutations.
J Med Chem 68: 11894-11915 (0)
Sichuan University
Heparan Sulfate-Based Neoproteoglycan for Targeted Lysosomal Degradation of Amyloid-β.
J Med Chem 68: 11979-11989 (0)
Indian Institute of Science Education and Research
A "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors.
J Med Chem 68: 12004-12028 (0)
Eberhard Karls Universitat Tubingen
XPO1-Targeting Selective Inhibitors of Transcriptional Activation Suppress Graft-versus-Host Disease.
J Med Chem 68: 12141-12171 (0)
Case Western Reserve University
The Discovery of C7-Substituted Norbornyl Bisamides as RXFP1 Small Molecule Agonists.
J Med Chem 68: 12185-12203 (0)
Bristol Myers Squibb, Co.
Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer.
J Med Chem 68: 12296-12330 (0)
National and Kapodistrian University of Athens (NKUA)
Validation, Key Pharmacophores, and X-ray Cocrystal Structures of Novel Biochemically and Cellularly Active WRN Inhibitors Derived from a DNA-Encoded Library Screen.
J Med Chem 68: 12434-12456 (0)
Abbvie
Discovery of a Selective, Novel TGF-βR1 Inhibitor GFH018 for the Treatment of Solid Tumors.
J Med Chem 68: 12513-12530 (0)
GenFleet Therapeutics (Zhejiang) Co. Ltd.
Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
J Med Chem 68: 12593-12614 (0)
Southern Medical University
Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy.
J Med Chem 68: 12687-12707 (0)
Germany.F. Hoffmann-La Roche Ltd
Could Hydrophobicity of Sulfated Pseudo-Trisaccharides Derived from Repurposing Aminoglycoside Tobramycin Modulate the Enzymatic Activity of Heparanase?
J Med Chem 68: 12708-12732 (0)
Wayne State University
Discovery and Optimization of Potent PROTAC Degraders of Phosphoinositide 3-Kinase with Significant in Vivo Anticancer Efficacy.
J Med Chem 68: 12800-12818 (0)
Chinese Academy of Medical Sciences and Peking Union Medical College
Discovery of KDX1381, a Bivalent CK2α Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination.
J Med Chem 68: 12819-12844 (0)
Kairos Discovery
Discovery of APH02174 as a Highly Selective and Orally Bioavailable IRAK4 Degrader for the Treatment of Inflammatory Diseases.
J Med Chem 68: 12845-12861 (0)
Sun Yat-sen University
Discovery of TBK1Molecular Glue Degraders as a Potential Strategy for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
J Med Chem 68: 12862-12880 (0)
Jinan University
Design and Synthesis of PARP/CDK6 Dual-Target Inhibitors Modulating of Wnt/β-Catenin Signaling Pathway for the Treatment of BRCA Wild-Type TNBC.
J Med Chem 68: 13030-13056 (0)
China Pharmaceutical University
Searching for Synthetic Opioid Rescue Agents. 2: Identification of an Ultra-Potent Synthetic Opioid Rescue Agent.
J Med Chem 68: 13057-13074 (0)
University of Kentucky